Participate in Research at CU Anschutz

We are conducting a study to compare the safety and efficacy of a single infusion of hyperimmune immunoglobulin (antibodies against COVID-19) versus placebo to prevent progression of COVID-19 in high-risk patients.

This outpatient study involves recently diagnosed COVID-19 patients to determine if a single infusion of antibodies can help prevent disease progression. In this placebo-controlled trial, 50% of participants will receive the antibodies, while the other half will receive saline. Neither the patients nor the study staff will know which group the patients are assigned to. We are focusing on higher-risk patients whose immune systems may not be primed to fight the virus efficiently. Patients will be monitored for 28 days with intermittent follow-up phone calls. Seven days after the infusion, a mobile lab will visit the patient's home to collect additional biospecimen samples (blood, saliva, and nasal swab).